Review
Biochemistry & Molecular Biology
Blassan P. George, Rahul Chandran, Heidi Abrahamse
Summary: Cancer chemoprevention involves using external agents to slow down or suppress cancer growth, and the occurrence of global cancer types varies depending on factors such as environmental, lifestyle, and genetic factors. Developed countries can prevent cancer with advanced treatment modalities, while developing countries often see it as a painful death sentence.
Article
Health Care Sciences & Services
Jeremy S. S. Paige, Christoph I. I. Lee, Pin-Chieh Wang, William Hsu, Adam R. R. Brentnall, Anne C. C. Hoyt, Arash Naeim, Joann G. G. Elmore
Summary: This study compared the accuracy and agreement of three breast cancer risk prediction models and found substantial variability in individual risk categorization. Depending on the model and risk threshold used, there were significant differences in breast cancer risk estimates for individuals. This variability can have adverse effects on screening, prevention, and quality of life, and clinicians need to be aware of the differences between models and the false-positive and false-negative rates when discussing with patients.
JOURNAL OF GENERAL INTERNAL MEDICINE
(2023)
Article
Nanoscience & Nanotechnology
Chunyan Liao, Xiang Wang, Xueying Zhou, Dequan Wang, Ziyin Zhang, Yan Liu, Xiao Wu, Ying Chen, Yifeng Tan, Xin Dai, Pei Jing, Jie Pang, Xiao Xiao, Jie Liu, Xiaoming Liao, Shiyong Zhang
Summary: Researchers have developed a nanodrug, VC@cLAV, which utilizes vitamin C (VC) and lipoic acid (LA) to efficiently kill cancer cells while protecting noncancer cells. The drug generates reactive oxygen species in cancer cells, leading to their destruction, while acting as an antioxidant in noncancer cells to prevent and repair oxidative stress-induced damage. Compared to traditional cytotoxic drugs, VC@cLAV demonstrates superior therapeutic outcomes and lacks side effects in various tumor models.
ACS APPLIED MATERIALS & INTERFACES
(2022)
Review
Biochemistry & Molecular Biology
Martina Cizmarikova, Radka Michalkova, Ladislav Mirossay, Gabriela Mojzisova, Martina Zigova, Annamaria Bardelcikova, Jan Mojzis
Summary: This review summarizes the role of ellagic acid (EA) as a potential therapeutic agent in cancer prevention and treatment by targeting key hallmarks of cancer. The multifaceted actions of EA make it a promising candidate for cancer prevention and therapy.
Review
Biochemistry & Molecular Biology
Marina Ibragimova, Matvey Tsyganov, Nikolai Litviakov
Summary: This review discusses the main mechanisms of CSCs in breast cancer, including markers and signaling pathways, heterogeneity, plasticity, and ecological behavior. The study also considers the significance of dynamic heterogeneity of CSCs and dynamic transitions between CSCs and non-CSCs for metastasis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Elizabeth R. M. Zunica, Christopher L. Axelrod, John P. Kirwan
Summary: Breast cancer is a common and deadly disease, with better prognosis for early-stage and less aggressive subtypes. However, aggressive subtypes have limited treatment options and responses, leading to decreased survival. Phytochemicals, with chemopreventive, therapeutic, and sensitizing properties, have the potential for treatment, management, and prevention of breast cancer. Targeting mitochondria, phytochemicals can enhance anti-breast cancer efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
Lyndsey A. Reich, Jessica A. Moerland, Ana S. Leal, Di Zhang, Sarah Carapellucci, Beth Lockwood, Peter W. Jurutka, Pamela A. Marshall, Carl E. Wagner, Karen T. Liby
Summary: Rexinoids, ligands that activate RXRs, have shown potential as cancer therapeutics. In this study, a novel rexinoid V-125 demonstrated significant anti-tumor activity in breast and lung cancer mouse models, while also showing improved safety compared to the FDA-approved rexinoid bexarotene. These findings validate the screening paradigm and suggest that V-125 could be developed as a new cancer therapeutic.
SCIENTIFIC REPORTS
(2022)
Article
Biochemistry & Molecular Biology
Mona A. Marie, Edward J. Sanderlin, Swati Satturwar, Heng Hong, Kvin Lertpiriyapong, Deepak Donthi, Li Yang
Summary: GPR65, as a proton-sensing G protein-coupled receptor mainly expressed in immune cells, plays a suppressing role in intestinal inflammation and colitis-associated colorectal cancer (CAC). Knockout of GPR65 leads to aggravated inflammation and increased colorectal cancer development. Increased expression of GPR65 gene was observed in inflamed intestinal tissue samples of IBD patients. The findings suggest a potential therapeutic effect of potentiation of GPR65 with agonists in IBD and reducing the risk of colitis-associated colorectal cancer.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2022)
Article
Oncology
Courtney Macdonald, James A. Chamberlain, Danielle Mazza, Roger L. Milne, Kelly-Anne Phillips
Summary: The study found that only a small percentage of Australian women have used breast cancer risk reducing medication, with higher breast cancer risk significantly associated with the use of such medication, while factors like parity, education level, and family history were not correlated. Efforts are needed to incorporate breast cancer risk assessment and management discussions into routine health assessments for women.
Review
Biochemistry & Molecular Biology
Nitin T. Telang
Summary: The progression of early stage breast and colon cancer to metastatic disease is a major cause of mortality in women. Development of drug-resistant cancer stem cell models is needed to overcome the limitations of current chemotherapy and targeted therapies. Dietary phytochemicals show growth inhibitory efficacy for cancer stem cells, offering new therapeutic alternatives for therapy-resistant breast and colon cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Gabriel Mendez-Valdes, Francisca Gomez-Hevia, Maria Chiara Bragato, Jose Lillo-Moya, Catalina Rojas-Sole, Luciano Saso, Ramon Rodrigo
Summary: Breast cancer is the most common malignant neoplastic disease in women, and its treatment depends on patient and tumor characteristics. The overexpression of the HER2 receptor, found in 15-25% of tumors, is associated with aggressive behavior and poor prognosis. Trastuzumab, a monoclonal antibody used as targeted therapy against HER2 receptor overexpression, has a major concern of cardiotoxicity. This review aims to explore the use of antioxidants as adjuvant therapy to prevent trastuzumab-induced cardiac toxicity and improve its safety profile.
Article
Biochemistry & Molecular Biology
Maria Lambouras, Charlotte Roelofs, Melrine Pereira, Emily Gruber, Jessica L. Vieusseux, Patrick Lanteri, Cameron N. Johnstone, Fenella Muntz, Sandra O'Toole, Lisa M. Ooms, Christina A. Mitchell, Robin L. Anderson, Kara L. Britt
Summary: Estrogen receptor-positive breast cancers (ER+ BCas) are increasing in incidence due to changes in reproductive practices. Tamoxifen, the standard endocrine therapy, is poorly tolerated, hindering prevention. Alternative therapies are needed but lack mouse models for pre-clinical research.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Rickard Strandberg, Linda Abrahamsson, Gabriel Isheden, Keith Humphreys
Summary: This article summarizes approaches for estimating tumour progression models inspired by biological arguments. These models can be used in personalized screening studies. The article also describes a simulation study that explores the impact of extending the age of screening invitation. The results show that both the current and extended screening programs can effectively reduce breast cancer mortality.
Article
Biochemistry & Molecular Biology
Patricia Oteiza, Cesar G. Fraga, Monica Galleano
Summary: The review explores the relationship between flavonoid consumption, oxidative stress mitigation, and improvement of human diseases. It focuses on the role of (-)-epicatechin in inflammation, endothelial dysfunction/hypertension, and insulin resistance/diabetes, and discusses the indirect antioxidant actions of EC and its metabolites in these pathologies. Human studies show promising results regarding the beneficial effects of EC on disease biomarkers, but more research is needed to establish conclusive associations between oxidative stress biomarkers and flavonoid consumption. The discovery of metabolites as reliable markers of flavonoid intake offers a powerful tool for linking flavonoid consumption to disease prevention and oxidative stress mitigation in human populations.
Review
Oncology
Shafiul Haque, Arif Hussain, Hemant Joshi, Ujjawal Sharma, Bunty Sharma, Diwakar Aggarwal, Isha Rani, Seema Ramniwas, Madhu Gupta, Hardeep Singh Tuli
Summary: This article provides mechanistic insights into the chemopreventive activity of melittin and its nanoversion in combination with standard anti-cancer drugs for the treatment of cancer. The anti-cancer effects of melittin on different cancers and their possible mechanisms of action have been discussed, including its interaction with different signal molecules that regulate the diverse pathways of cancerous cells. The article also discusses the recent progress in the synergistic combination of melittin with standard anti-cancer drugs and a nano-formulated version of melittin for targeted delivery to improve its anticancer potential.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Medicine, Research & Experimental
Lucia Recinella, Annalisa Chiavaroli, Serena Veschi, Valentina Di Valerio, Rossano Lattanzio, Giustino Orlando, Claudio Ferrante, Iacopo Gesmundo, Riccarda Granata, Renzhi Cai, Wei Sha, Andrew V. Schally, Luigi Brunetti, Sheila Leone
Summary: The MIAMI class GHRH antagonist MIA-690 was shown to suppress the progression and growth of colorectal cancer (CRC) by reducing inflammatory and oxidative markers, modulating apoptotic and oncogenic pathways, and improving survival rates in mice. Further research is needed to explore the translation of these findings into clinical applications.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Biochemistry & Molecular Biology
Emanuela Guerra, Roberta Di Pietro, Mariangela Basile, Marco Trerotola, Saverio Alberti
Summary: CAR-T therapy, which utilizes engineered patient blood cells, has shown great success in treating leukemia but faces challenges in treating solid tumors, including difficulties in trafficking the CAR-T cells to the tumor site and the hostile environment presented by cancer cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Emanuela Guerra, Valeria Relli, Martina Ceci, Romina Tripaldi, Pasquale Simeone, Anna Laura Aloisi, Ludovica Pantalone, Rossana La Sorda, Rossano Lattanzio, Andrea Sacchetti, Kristina Havas, Simone Guarnieri, Daniele Vergara, Isabelle Fournier, Michel Salzet, Nicola Tinari, Mauro Piantelli, Marco Trerotola, Saverio Alberti
Summary: This study investigates the molecular mechanisms of Trop-2 signaling in colorectal cancer and uncovers a novel feed-forward signaling involving the interaction between Trop-2 and Na+/K+-ATPase, leading to malignant progression of cancer cells.
Article
Gastroenterology & Hepatology
Maria Chiara De Santis, Luca Gozzelino, Jean Piero Margaria, Andrea Costamagna, Edoardo Ratto, Federico Gulluni, Enza Di Gregorio, Erica Mina, Nicla Lorito, Marina Bacci, Rossano Lattanzio, Gianluca Sala, Paola Cappello, Francesco Novelli, Elisa Giovannetti, Caterina Vicentini, Silvia Andreani, Pietro Delfino, Vincenzo Corbo, Aldo Scarpa, Paolo Ettore Porporato, Andrea Morandi, Emilio Hirsch, Miriam Martini
Summary: This study reveals that loss of PI3K-C2 gamma in pancreatic ductal adenocarcinoma (PDAC) leads to hyperactivation of mTORC1 pathway and rewiring of glutamine metabolism, increasing tumor aggressiveness. Furthermore, PI3K-C2 gamma knockout tumors fail to adapt to metabolic stress induced by glutamine depletion, resulting in cell death. These findings suggest that targeting mTORC1 and glutamine metabolism may be a potential strategy for personalized treatment in PDAC with PI3K-C2 gamma loss.
Article
Biochemistry & Molecular Biology
Alice Turdo, Miriam Gaggianesi, Simone Di Franco, Veronica Veschi, Caterina D'Accardo, Gaetana Porcelli, Melania Lo Iacono, Irene Pillitteri, Francesco Verona, Gabriella Militello, Alessio Zippo, Vittoria Poli, Luca Fagnocchi, Sven Beyes, Stefania Stella, Rossano Lattanzio, Naida Faldetta, Vincenzo L. Lentini, Rossana Porcasi, Giuseppe Pistone, Maria Rita Bongiorno, Giorgio Stassi, Ruggero De Maria, Matilde Todaro
Summary: Breast cancer is the second leading cause of cancer-related deaths in women worldwide. In a study using breast cancer stem-like cells as a model, high levels of Myc were found to be expressed, and the multifunctional DNA/RNA binding protein Sam68 was shown to play a role in DNA damage repair. Inhibiting Sam68 caused cell death in breast cancer stem-like cells, but these cells were able to survive through upregulation of Rad51. Thus, targeting the Sam68-PARP1 axis and Rad51 may be potential therapeutic candidates for combating the expansion of aggressive breast cancer cells.
Editorial Material
Oncology
Emanuela Guerra, Saverio Alberti
ANNALS OF TRANSLATIONAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Conception Paul, Ruizhi Tang, Ciro Longobardi, Rossano Lattanzio, Thibaut Eguether, Hulya Turali, Julie Bremond, Chloe Maurizy, Monica Gabola, Sophie Poupeau, Andrei Turtoi, Emilie Denicolai, Maria Concetta Cufaro, Magali Svrcek, Philippe Seksik, Vincent Castronovo, Philippe Delvenne, Vincenzo de Laurenzi, Quentin Da Costa, Francois Bertucci, Benedicte Lemmers, Damiana Pieragostino, Emilie Mamessier, Carsten Janke, Valerie Pinet, Michael Hahne
Summary: This study found that a decrease in primary cilia numbers in the colon promotes colitis and colorectal cancer, and an activation loop may exist between the inflammatory environment and IL-6 production in relation to primary cilia loss.
Correction
Multidisciplinary Sciences
Chloe Maurizy, Claire Abeza, Benedicte Lemmers, Monica Gabola, Ciro Longobardi, Valerie Pinet, Marina Ferrand, Conception Paul, Julie Bremond, Francina Langa, Francois Gerbe, Philippe Jay, Celine Verheggen, Nicola Tinari, Dominique Helmlinger, Rossano Lattanzio, Edouard Bertrand, Michael Hahne, Berengere Pradet-Balade
NATURE COMMUNICATIONS
(2022)
Article
Biochemistry & Molecular Biology
Marco Pieraccioli, Cinzia Caggiano, Luca Mignini, Chuwei Zhong, Gabriele Babini, Rossano Lattanzio, Savino Di Stasi, Bin Tian, Claudio Sette, Pamela Bielli
Summary: The selection of polyadenylation signals and alternative polyadenylation (APA) play important roles in gene expression regulation. This study uncovers a mechanism of APA regulation involving the interaction between XRN2 exonuclease and Sam68 RNA-binding protein. The increased expression of Sam68 in prostate cancer, promoted by MYC, leads to the usage of suboptimal proximal polyadenylation signals and enhances cell cycle-related gene translation. This finding suggests that the Sam68/XRN2-driven APA program may be a potential target for therapeutic strategies.
NATURE STRUCTURAL & MOLECULAR BIOLOGY
(2022)
Article
Oncology
Emanuela Guerra, Marco Trerotola, Valeria Relli, Rossano Lattanzio, Romina Tripaldi, Martina Ceci, Khouloud Boujnah, Ludovica Pantalone, Andrea Sacchetti, Kristina M. Havas, Pasquale Simeone, Nicole Travali, Patrizia Querzoli, Massimo Pedriali, Pietro Roversi, Manuela Iezzi, Nicola Tinari, Laura Antolini, Saverio Alberti
Summary: Trop-2 undergoes proteolytic activation by ADAM10 in cancer cells, exposing a previously inaccessible protein groove. A recognition strategy was designed to selectively target cancer cells. A cancer-specific antibody, 2G10, was generated and humanized into Hu2G10, which showed high affinity for cleaved/activated Trop-2 in cancer cells and moderate affinity for uncleaved/wtTrop-2 in normal cells. Hu2G10 effectively inhibited the growth of Trop-2-expressing breast, colon, and prostate cancers in vivo without causing systemic toxicity.
MOLECULAR CANCER THERAPEUTICS
(2023)
Article
Oncology
Emanuela Guerra, Marco Trerotola, Saverio Alberti
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Dentistry, Oral Surgery & Medicine
Ilaria Cela, Vito Carlo Alberto Caponio, Emily Capone, Morena Pinti, Marco Mascitti, Lucrezia Togni, Lorenzo Lo Muzio, Corrado Rubini, Vincenzo De Laurenzi, Rossano Lattanzio, Vittoria Perrotti, Gianluca Sala
Summary: The present study suggests that LGALS3BP is highly expressed in oral squamous cell carcinoma (OSCC) and may serve as a potential diagnostic biomarker and therapeutic target for ADC-based therapy. The study also found a correlation between high LGALS3BP expression levels and aggressive histological features of OSCC. Additionally, OSCC cell lines with high LGALS3BP expression showed high sensitivity to the ADC-payload DM4.
Article
Oncology
Emanuela Guerra, Marco Trerotola, Valeria Relli, Rossano Lattanzio, Martina Ceci, Khouloud Boujnah, Ludovica Pantalone, Roberta Di Pietro, Manuela Iezzi, Nicola Tinari, Saverio Alberti
Summary: We developed the 2EF mAb to recognize Trop-2 in difficult-to-reach, densely packed tumor sites. The 2EF antibody efficiently accessed Trop-2 at cell-cell junctions in breast cancer cells and inaccessible sites in prostate tumors. It showed high anticancer activity on densely packed, Trop-2-expressing tumors and enhanced the activity of the 2G10 mAb against tumors in vivo.
Article
Genetics & Heredity
Marco Trerotola, Laura Antolini, Laura Beni, Emanuela Guerra, Mariano Spadaccini, Damiano Verzulli, Antonino Moschella, Saverio Alberti
Summary: The determinants of transcription factor amino acid-DNA base binding selectivity were identified, and a DNA recognition mode was discovered. This advances our understanding of gene expression regulation and has the potential for integration with higher-order complexity approaches.
NAR GENOMICS AND BIOINFORMATICS
(2022)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)
